HIV Prevention Research and Development Investments, 2000–2016: Investment Priorities to Fund Innovation in a Challenging Global Health Landscape

Publications - Released in 2017

In its 13th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group ("Working Group") documents research and development spending for the calendar year 2016 and analyzes funding trends spanning 16 years.

Between 2000 and 2016, the Working Group has tracked over US$17 billion in investment towards biomedical HIV prevention research and development (R&D1) (Figure 1). The 2016 report analyzes over 600 donor-identified disbursements, as well as R&D spending trends for the following prevention options: AIDS vaccines, microbicides, pre-exposure prophylaxis (PrEP), treatment as prevention (TasP), medical male circumcision (VMMC), female condoms, prevention of vertical transmission (PMTCT) and HSV-2 vaccines. Cure research and therapeutic vaccine investments were also tracked as part of a comprehensive analysis of the HIV R&D landscape.

In a constantly evolving field, the Working Group estimates serve as a comparative cross-sectional and retrospective analysis of interventions, funding sources and strategies to evaluate the impact of public policies and to provide support for advocacy. This work also provides the transparency needed for funders, policy makers and HIV/AIDS advocates to best understand HIV prevention R&D investment flows and to generate strategies for the future.

Downloads

 Download Report(2.68 MB)

Organizations

  • HIV Resource Tracking
  • AIDS Vaccine Advocacy Coalition (AVAC)
  • International AIDS Vaccine Initiative (IAVI)
  • Joint United Nations Programme on HIV/AIDS (UNAIDS)
  • United States President′s Emergency Plan for AIDS Relief (PEPFAR)
  • United States Agency for International Development (USAID)